|
Serum (mean AUC and 95% confidence intervals)
|
Oral fluid (mean AUC and 95% confidence intervals)
|
---|
Trial (virus isolate)
|
qRT-PCR
|
IgM
|
IgA
|
IgG
|
qRT-PCR
|
IgM
|
IgA
|
IgG
|
Trial 1: (Ingelvac® PRRS MLV)
|
21.6b
|
46.6b
|
18.5b
|
17.4a
|
21.0b
|
27.6b
|
12.3b
|
25.1b
|
(18.8-24.5)
|
(43.1-50.2)
|
(14.6-22.6)
|
(15.9-18.9)
|
(17.0-25.1)
|
(23.9-31.5)
|
(7.7-17.0)
|
(20.6-29.6)
|
Trial 2: (Type 1, D09-012332)
|
23.8b
|
39.5b
|
30.0a
|
18.3a
|
21.2b
|
17.6c
|
17.9b
|
21.9b
|
(21.2-26.6)
|
(31.1-48.0)
|
(23.2-36.9)
|
(16.5-20.2)
|
(18.1-24.3)
|
(12.0-23.2)
|
(10.9-24.9)
|
(16.7-27.2)
|
Trial 3: (Type 2, MN-184)
|
38.1a
|
53.7a
|
31.6a
|
18.4a
|
31.6a
|
35.4a
|
26.2a
|
30.1a
|
(34.9-41.5)
|
(48.1-59.3)
|
(24.7-38.5)
|
(17.1-19.85)
|
(28.4-34.9)
|
(28.6-42.3)
|
(19.1-33.5)
|
(25.3-34.9)
|
- 1 Individual boar PRRSV (loge geq/μl) and antibody (IgM, IgA, IgG) S/P responses over time were summarized as the area under the curve (AUC) prior to performing the statistical analysis.
- abc Superscripts within columns indicate statistically significant differences among means (Tukey’s Honestly Significant Differences test, p < 0.05).